Results 31 to 40 of about 1,651 (123)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis

Drugs - Real World Outcomes, 2020
Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial treatment of osteomyelitis is fraught with multiple challenges and ...
Patrick J. Scoble, Joseph Reilly, Glenn S. Tillotson   +2 more
doaj   +1 more source

Glycopeptide Antibiotics: Structural and Functional Aspects, Human Medicinal Use, and Standardisation

Регуляторные исследования и экспертиза лекарственных средств, 2023
In recent years, glycopeptide antibiotics have been widely used to treat severe bacterial infections. The long-term use of first-generation antibiotics of this group (vancomycin, teicoplanin) has contributed to the emergence of bacteria resistant to them.
O. N. Vysochanskaya, S. I. Kuleshova, E. P. Simonova   +2 more
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie International Edition, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +1 more source

Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria

Angewandte Chemie, Volume 137, Issue 25, June 17, 2025.
A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur, Jaime Felipe Guerrero‐Garzón, Sari Rasheed, Martin Zehl, Franziska Fries, Bernd Morgenstern, Sergey B. Zotchev, Rolf Müller   +7 more
wiley   +2 more sources

Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement

Infectious Diseases and Therapy
Introduction Weekly intravenous (IV) oritavancin and daily daptomycin were compared in an outpatient setting following extensive surgical debridement for treating patients with osteomyelitis.
Nicholas W. Van Hise, Russell M. Petrak, Kairav Shah, Melina Diaz, Vishnu Chundi, Mark Redell   +5 more
doaj   +1 more source

Novel and emerging antimicrobial strategies in the management of oral infections

Periodontology 2000, EarlyView.
Abstract Background Antibiotics marked a pivotal turning point in human civilization, enhancing social interactions and extending human life expectancy. In addition to their success in treating systemic infectious diseases, they have significantly improved periodontal treatment outcomes as an adjunct therapy.
Ozge Unlu, Nil Yakar, Alpdogan Kantarci
wiley   +1 more source

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus

Antibiotics, 2020
Within a sufficiently large bacterial population, some members will naturally adopt an alternate, metabolically-active state that favors small molecule synthesis over cell division.
Andrew D. Berti, Lauren T. Harven, Victoria Bingley   +2 more
doaj   +1 more source

Clinically Approved Antibiotics from 2010 to 2022

CHIMIA, 2023
This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives ...
Erik Jung, Karl Gademann
doaj   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, Volume 38, Issue 51, 11 September 2026.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

Oritavancin as sequential therapy for Gram-positive bloodstream infections

BMC Infectious Diseases
Background Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms.
Williams Monier Texidor, Matthew A. Miller, Kyle C. Molina, Martin Krsak, Barbara Calvert, Caitlin Hart, Marie Storer, Douglas N. Fish   +7 more
doaj   +1 more source